Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

May 2013 Array BioPharma (ARRY) entered into a Development and Commercialization Agreement with Oncothyreon (ONTY) to collaborate on development and commercialization of ONT380 for the treatment of cancer (previously known also as ARRY380). Upfront Payment Oncothyreon paid Array a onetime fee of $10MM This agreement was terminated effective December 11, 2014. December 2014, Array BioPharma […]

July 2013, Array BioPharma (ARRY) entered into a Drug Discovery Collaboration Agreement with Loxo Oncology (LOXO) @LoxoOncology, and granted Loxo exclusive rights to develop and commercialize certain Array invented compounds targeted at the tropomyosin kinase (“Trk”) family of receptors, including LOXO-101. In April 2014 and again in April 2015, Array and Loxo amended the agreement […]

November 2013, Clovis Oncology ($CLVS @ClovisOncology) acquired Ethical Oncology Science, S.p.A. (“EOS”) (known as Clovis Oncology Italy S.r.l., or “COI”) through which the rights to lucitanib were obtained. 2008, EOS had in-licensed exclusive development and commercial rights to lucitanib on a global basis, excluding China, from Advenchen Laboratories. September 2012, EOS entered into a collaboration and license […]

June 2011, Clovis Oncology ($CLVS @ClovisOncology) entered into a license agreement with Pfizer ($PFE @Pfizer) to obtain exclusive global rights to develop and commercialize rucaparib. The rights are exclusive even as to Pfizer and include the right to grant sublicenses. Upfront Payment $7.0MM Milestone 1 $0.4MM, April 2014, for the initiation of ARIEL3 pivotal registration study Milestone 2.0 $88.5MM […]

Kiadis Pharma (Netherlands), a clinical-stage biopharmaceutical company developing treatments for blood cancers, closed a $12.8M Series D financing. Participants include Life Sciences Partners, DFJ-Esprit, Alta Partners, Quest for Growth and NOM.

Innovent Biologics (China), a clinical stage biotechnology company focused on the development of monoclonal antibodies targeting various diseases, closed a $25M Series B financing. Participants include Lilly Asia Ventures, Fidelity Biosciences and Fidelity Growth Partners Asia.

MabVax Therapeutics (San Diego, CA), a clinical-stage biotechnology company focused on cancer immunotherapies, closed a $5.3M Series B financing. Participants include Numoda Capital Innovations, Burrill & Co. and RTP Venture Fund. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive […]

Epic Sciences (San Diego, CA), a preclinical-stage biotechnology company focused on cancer diagnostics, closed a $13M Series B financing. Participants include Domain Associates, Roche Venture Fund, and Pfizer Venture Investments. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective […]

Metamark Genetics (Cambridge, MA), a preclinical-stage molecular diagnostics company focused on cancer, closed a $13M Series B financing. Participants were not identified. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account Access HERE

Ambit Biosciences (San Diego, CA), a clinical-stage biotechnology company focused on kinase-based therapeutics for cancer, closed a $25M Series E financing. Participants include OrbiMed Advisors, Aisling Capital, Apposite Healthcare, Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV, and Radius Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate […]

Alethia Biotherapeutics (Canada), a preclinical-stage biotechnology company focused on bone degredation, closed a $4.7M Series B financing. Participants include AgeChem Venture Fund, BDC Venture Capital and GO Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account […]

Gliknik (Baltimore, MD), a clinical-stage biotechnology company focused on treatments for cancer and autoimmune diseases, closed a $4.9M Series B financing. Participants include Baxter Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Principia Biopharma (San Francisco, CA), a biopharmaceutical company focused on immunology, autoimmune diseases and oncology, closed a $12.5M Series A financing, bringing the total round to $36.6M. Participants include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SR One and Mission Bay Capital. Collective IP | The Most Comprehensive and Accurate View of Global Innovation […]

« Previous Entries  Next Page »

to top of page...